PRESS RELEASE
November 23, 2017
The Annual General Meeting on May 23, 2017, resolved that a Nomination Committee shall be appointed before coming election and remuneration. The Nomination Committee shall comprise three members, which should be representative for the two largest shareholders as of last September, together with the Chairman of the Board of Directors.
On September 30, 2017, the two largest shareholders, which desired to appoint a representative to the Nomination Committee, were Jørgen Drejer and Thomas Feldthus. Each such shareholder has appointed a representative, as shown below, who together with the Chairman of the Board of Directors will form Saniona AB's Nomination Committee.
The Nomination Committee's member are:
- Søren Skjærbæk, Partner at Saxo lawyers, Vejle, Denmark, appointed by Jørgen Drejer
- John Haurum, CEO of F-star Biotechnology Limited, Cambridge, UK, appointed by Thomas Feldthus
- Claus Bræstrup, Chairman of Saniona AB's Board
The Nomination Committee shall prepare and submit proposals to the 2018 Annual General Meeting regarding:
- election of the Chairman at the Annual General Meeting
- election of the Chairman and other members of the Board;
- remuneration for the Chairman and for each of the other members of the Board and, if applicable, remuneration for committee work;
- election of the auditor and the auditor's remuneration; and
- principles for appointing the Nomination Committee.
The instruction and charter for the Nomination Committee in Saniona AB can be found in the Corporate Governance section at the company's website, www.saniona.com.
Saniona AB's Annual General Meeting will be held on Tuesday May 24, 2018 in Malmö.
Shareholders who would like to submit proposals to the Nomination Committee can do so via e-mail to tf@saniona.com marked "Recommendation to the Nomination Committee" or by ordinary mail to the address:
Recommendation to the Nomination Committee
Saniona AB
Att. Thomas Feldthus
Baltorpvej 157
DK-2750 Ballerup
Denmark
To ensure that the proposals can be considered by the Nomination Committee, proposals shall be submitted in due time before the Annual General Meeting, but not later than 15 February 2018.
For more information, please contact
Thomas Feldthus, EVP and CFO, Saniona, Mobile: +45 2210 9957, E-mail: tf@saniona.com
The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET on November 23, 2017.
About Saniona
Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain. The company has a significant portfolio of potential drug candidates at pre-clinical and clinical stage. The research is focused on ion channels, which makes up a unique protein class that enables and controls the passage of charged ions across cell membranes. Saniona has ongoing collaboration agreements with Boehringer Ingelheim GmbH, Proximagen Ltd., Productos Medix, S.A de S.V and Cadent Therapeutics. Saniona is based in Copenhagen, Denmark, where it has a research center of high international standard. Saniona is listed at Nasdaq Stockholm Small Cap and has about 5,300 shareholders. The company's share is traded under the ticker SANION. Read more at www.saniona.com.
Attachments:http://www.globenewswire.com/NewsRoom/AttachmentNg/0fc566d3-df2e-4ab0-9ee3-53002ce0ee43
